No More Silos – PrEP is One Component of Gay Men’s Sexual Health: A Health Department Approach to PrEP

By Barry Callis, Director of Behavioral Health and Infectious Disease Prevention, Office of HIV/AIDS, Bureau of Infectious Disease and Dawn Fukuda, Director, Office of HIV/AIDS, Bureau of Infectious Disease, Massachusetts Department of Public Health

Barry Callis and Dawn Fukuda

Barry Callis and Dawn Fukuda

Many of us in the Office of HIV/AIDS at the Massachusetts Department of Public Health (MDPH) were huddled excitedly around our computer screens when the first reports of success from the iPrEx clinical trial were released. It was December of 2010, and at long last, we had confirmed proof that an antiviral medicine (Truvada) could protect against HIV infection before exposure, and that it worked for gay and bisexual men and transgender women. It was a possibility we had only dreamed of in the early 1990’s, when effective antiretrovirals were first widely available as treatment. Continue reading

How New York is Using Pre-Exposure Prophylaxis (PrEP) to End HIV

By Dan O’Connell, Director, AIDS Institute, New York State Department of Health

The AIDS Institute, New York State Department of Health

The AIDS Institute, New York State Department of Health

In June of this year, New York’s Governor, Andrew M. Cuomo, announced a plan to bring HIV below epidemic levels in New York State by 2020. In this plan, pre-exposure prophylaxis (PrEP) is identified as one of three key strategies for reducing new HIV infections to sub-epidemic levels, and is a great example of how health departments can bring the domestic HIV epidemic to its end within a rapidly changing system of HIV prevention and care services and raising the bars of the HIV care continuum. Continue reading

How Health Departments Are Modernizing HIV Prevention with Pre-Exposure Prophylaxis (PrEP)

By Christopher Cannon, Manager, Health Care Access, NASTAD

PrEPPrior to the approval of Truvada as PrEP, health departments feared there would be a rush of affluent gay men demanding access to Pre-Exposure Prophylaxis (PrEP)-the use of antiretroviral medication to prevent the infection of HIV-to abandon condom use altogether. In so doing, they would create greater health disparities among vulnerable populations like young gay and bisexual men, Black and Latino gay and bisexual men, and transgender women who are often disenfranchised. However interest in PrEP outside of clinical trials across the country has been very limited. Gilead, manufacturer of Truvada, reports only 2,319 prescriptions filled for Truvada as PrEP from January 1, 2012 (prior to FDA approval in July 2012) to September 30, 2013 in the United States, which currently has an estimated 50,000 HIV infections each year. Continue reading